scholarly journals Onasemnogene Abeparvovec (Zolgensma)

2021 ◽  
Vol 1 (9) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Single Dose ◽  
Cost Effectiveness ◽  
Pediatric Patients ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Survival Motor Neuron ◽  
Smn1 Gene ◽  
Smn2 Gene ◽  
Clinician Perspectives ◽  
Biallelic Mutations

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses onasemnogene abeparvovec (Zolgensma), given as a single-dose IV infusion of 1.1 × 1014 vector genomes/kg Indication: For the treatment of pediatric patients with 5q SMA with biallelic mutations in the survival motor neuron 1 (SMN1) gene and: 3 or fewer copies of the SMN2 gene or infantile-onset SMA  

scholarly journals Pembrolizumab (Keytruda)

2021 ◽  
Vol 1 (12) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Cost Effectiveness ◽  
Pediatric Patients ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Salvage Chemotherapy ◽  
Clinician Perspectives ◽  
Multi Agent

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses pembrolizumab (Keytruda) 200 mg in adults or 2 mg/kg in pediatrics administered intravenously every 3 weeks. Indication: Treatment of adult and pediatric patients with refractory or relapsed cHL, as monotherapy, who have failed ASCT, or who are not candidates for multi-agent salvage chemotherapy and ASCT.

scholarly journals Nivolumab (Opdivo) in combination with Ipilimumab (Yervoy)

2021 ◽  
Vol 1 (9) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Cost Effectiveness ◽  
Systemic Therapy ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Adult Patients ◽  
Clinician Perspectives ◽  
Prior Systemic Therapy

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses nivolumab (Opdivo) 10 mg/mL for injection; administered by IV infusion and ipilimumab (Yervoy) 5 mg/mL for injection; administered by IV infusion Indication: Nivolumab (Opdivo) in combination with ipilimumab (Yervoy) is indicated for the treatment of adult patients with unresectable MPM who have not received prior systemic therapy for MPM

scholarly journals Luspatercept (Reblozyl)

2021 ◽  
Vol 1 (8) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Cost Effectiveness ◽  
Blood Cell ◽  
Red Blood Cell ◽  
Subcutaneous Injection ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Adult Patients ◽  
Red Blood Cell Transfusion ◽  
Beta Thalassemia ◽  
Clinician Perspectives

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses luspatercept (Reblozyl), 25 mg/vial, 75 mg/vial, powder for solution for subcutaneous injection. Indication: For the treatment of adult patients with red blood cell transfusion-dependent anemia associated with beta-thalassemia.

scholarly journals Risperidone for Extended-Release Injectable Suspension (Perseris)

2021 ◽  
Vol 1 (11) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Cost Effectiveness ◽  
Subcutaneous Injection ◽  
Extended Release ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Clinician Perspectives

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses risperidone for extended-release injectable suspension (Perseris), powder for suspension, 90 mg or 120 mg subcutaneous injection. Indication: Treatment of schizophrenia in adults.

scholarly journals Larotrectinib (Vitrakvi)

2021 ◽  
Vol 1 (11) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Gene Fusion ◽  
Pediatric Patients ◽  
Drug Class ◽  
Treatment Options ◽  
Acquired Resistance ◽  
Resistance Mutation ◽  
Clinical Effectiveness ◽  
Oral Solution ◽  
Severe Morbidity ◽  
Clinician Perspectives

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses larotrectinib (Vitrakvi); 25 mg and 100 mg capsules (as larotrectinib sulphate) and 20 mg/mL oral solution (as larotrectinib sulphate). Indication: For the treatment of adult and pediatric patients with solid tumours that: have an NTRK gene fusion without a known acquired resistance mutation are metastatic or where surgical resection is likely to result in severe morbidity have no satisfactory treatment options

Venetoclax (Venclexta)

2021 ◽  
Vol 1 (10) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Cost Effectiveness ◽  
Induction Chemotherapy ◽  
Low Dose ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Newly Diagnosed ◽  
Clinician Perspectives ◽  
Low Dose Cytarabine

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses venetoclax (Venclexta), 10 mg, 50 mg, and 100 mg oral tablets. Indication: In combination with azacitidine or low-dose cytarabine for the treatment of patients with newly diagnosed AML who are 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.

scholarly journals Pembrolizumab (Keytruda)

2021 ◽  
Vol 1 (9) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Colorectal Cancer ◽  
Cost Effectiveness ◽  
Microsatellite Instability ◽  
Mismatch Repair ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Line Treatment ◽  
First Line ◽  
Clinician Perspectives ◽  
First Line Treatment

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses pembrolizumab (Keytruda) 200 mg administered intravenously Indication: As monotherapy, for the first-line treatment of adults with metastatic microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer

scholarly journals Upadacitinib (Rinvoq)

2021 ◽  
Vol 1 (10) ◽  
Author(s):  
Reimbursement Reviews
Keyword(s):  
Psoriatic Arthritis ◽  
Cost Effectiveness ◽  
Extended Release ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Inadequate Response ◽  
Clinician Perspectives

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses upadacitinib (Rinvoq) 15-mg extended-release oral tablets Indication: For the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other DMARDs; Rinvoq (upadacitinib) may be used as monotherapy or in combination with methotrexate

scholarly journals Daunorubicin and Cytarabine Liposome (Vyxeos)

2021 ◽  
Vol 1 (10) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Acute Myeloid Leukemia ◽  
Cost Effectiveness ◽  
Myeloid Leukemia ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Newly Diagnosed ◽  
Clinician Perspectives ◽  
Acute Myeloid

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses dunorubicin and cytarabine liposome for injection, 44 mg daunorubicin and 100 mg cytarabine per vial, IV infusion Indication: Treatment of adults with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes

scholarly journals Risdiplam (Evrysdi)

2021 ◽  
Vol 1 (11) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Cost Effectiveness ◽  
Spinal Muscular Atrophy ◽  
Drug Class ◽  
Muscular Atrophy ◽  
Clinical Effectiveness ◽  
Oral Solution ◽  
Clinician Perspectives

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses risdiplam (Evrysdi), powder for oral solution. Indication: Pre-NOC: for the treatment of spinal muscular atrophy; Final: for the treatment of spinal muscular atrophy in patients 2 months and older.

Sign in / Sign up

Export Citation Format

Share Document